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Abstract
APE1/Ref-1 protects cells from oxidative stress by acting as a central enzyme in base excision
repair pathways of DNA lesions and through its independent activity as a redox transcriptional co-
activator. Dysregulation of this protein has been associated to cancer development. At present,
contrasting data have been published regarding the biological relevance of the two functions as
well as the molecular mechanisms involved. Here, we combined both mRNA expression profiling
and proteomic analysis to determine the molecular changes associated with APE1 loss-of-
expression induced by siRNA technology. This approach identified a role of APE1 in cell growth,
apoptosis, intracellular redox state, mitochondrial function and cytoskeletal structure. Thus,
overall, our data show that APE1 acts as a hub in coordinating different and vital functions in
mammalian cells, highlighting the molecular determinants of the multifunctional nature of APE1
protein.
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1. Introduction
APE1/Ref-1 (henceforth referred to as APE1) is a master regulator of cellular response to
oxidative stress and plays a central role in the maintenance of the genome stability. The vital
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effects of APE1 appear to be attributable to its role in the base excision repair (BER)
pathways of DNA lesions [1]. However, the biological relevance of APE1 in eukaryotic
transcriptional regulation of gene expression as a redox co-activator of different
transcription factors, such as Egr-1, NF-κB, p53, AP-1 and others [2], has yet to be
elucidated. APE1 biological activities are exerted by two functionally distinct domains [2–
4]. The N-terminus, containing the nuclear localization signal sequence, is principally
devoted to the redox transcriptional co-activation activity [5], while the C-terminus exerts
the enzymatic activity on the abasic sites of DNA [6].
Several reports indicated that dysregulation of APE1 expression is associated to different
tumorigenic processes [2]. In particular, a higher intracellular expression and a robust
cytoplasmic localization of APE1 have been described in lung, ovarian, thyroid and breast
cancers [2], where they correlate with a higher aggressiveness of the tumors. The possible
causal role played by this particular distribution in tumor progression is currently unknown.
However, APE1 ability to activate transcription factors, such as p53 and Egr-1 [2, 7–9],
which are mainly involved in controlling cell-cycle-arrest and apoptotic programs, leaves
the debate open about the mechanisms responsible for controlling its different functions in
several contexts.
APE1 is essential for cell viability. Genetic knockout of APE1 in mice causes post-
implantation embryonic lethality [10, 11] and any attempt to isolate stable APE1-knockout
cell lines has been so far unsuccessful. For these reasons, achieving a comprehensive
understanding of the molecular targets mediating APE1 functions has been very difficult. In
the last two years, however, conditional knockout and knockdown strategies [1, 12]
confirmed the essentiality of this protein for cell life and allowed establishment of cell
models to inspect and characterize the major functions of APE1. Nonetheless, complete
knowledge of molecular effectors regulated by APE1 in determining its biological roles is
still scanty. The essentiality of APE1 for mammalian cells seems to be mainly due to its
DNA-repair activity in BER pathway. However, attempts to restore this activity in cells not
expressing APE1 by using the yeast homologous Apn1 [1], which lacks the redox-
transcriptional activation domain, or an APE1 mutant lacking the acetylation sites but not
the DNA-repair activity [12], were unsuccessful. By specifically blocking the APE1 redox
activity with the drug E3330, but not its DNA repair activity, very recently it has been
shown that cytokine-mediated hemangioblast development in vitro was significantly
impaired [13]. These observations led us to hypothesize that essentiality of APE1 may be
due to its pleiotropic biological effects rather than merely to its DNA-repair activity.
In this work, we have identified changes at the proteome and transcriptome level associated
with the loss of APE1 expression in HeLa cells by using conditional RNAi technology and
an unbiased comparative approach of proteomic and microarray analysis. Our data shed light
on some of the molecular aspects mediating the biological effects of the multifunctional
APE1. This is the first large-scale attempt to dissect the roles of APE1 both at gene
expression and protein level and provide the basis for future studies on the comprehension
of the role played by this protein in regulating different biological mechanisms through the
control of signal transduction pathways and gene expression.
2. Materials and methods
2.1. Inducible siRNA of APE1 in HeLa cell line
The oligonucleotides used for siRNA of APE1 were as follows: sense, 5’-
GATCCCCCCTGCCACACTCAAGATCTGCTTCAAGAGAGCAGATCTTGAGTGTGG
CAGGTTTTTGGAAA-3’; antisense, 5’-
AGCTTTTCCAAAAACCTGCCACACTCAAGATCTGCTCTCTTGAAGCAGATCTTGA
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GTGTGGCAGGGGG-3’. These sequences were drawn following the empirical rules of
Mittal [14] and were designed to recognize and bind to a 21 base sequence (underlined)
placed 175 nucleotides after the AUG initiation codon of APE1 gene. As a control, we used
the scrambled oligonucleotide sequences: sense, 5’-
GATCCCCAGTCTAACTCGCCACCCCGTATTCAAGAGATACGGGGTGGCGAGTTA
GA CTTTTTTGGAAA-3’; antisense, 5’-
AGCTTTTCCAAAAAAGTCTAACTCGCCACCCCGTATCTCTTGAATACGGGGTGG
CG AGTTAGACTGGG-3’. These sequences were checked with BLAST (http://
www.ncbi.nlm.nih.gov/blast/) for their inability to pair any human cDNA sequence. The
sequences were cloned into BglII and HindIII restriction sites of the pTer vector [15], which
presents a tetracycline- (doxycycline-) responsive promoter to form the so called pTer/APE1
vector and pTer/Scr, respectively. In a first step, HeLa cells were transfected with pcDNA6/
TR to generate stable Tet-repressor expressing cell clones that were selected for the acquired
resistance by incubation with blasticidin (5 µg/ml) (Invitrogen, Milan, Italy) for 14 days.
Individual clones were isolated by using cell cloning cylinders (Sigma, Milan, Italy)
transferred and grown stepwise into 24-well, 12-well, 6-well plates for expansion to 107
cells. Clone TR5 was shown to express the Tet-repressor at higher levels and was therefore
selected for transfection with pTer/APE1 vector previously linearized with Bst1107I
(Fermentas, St.Leon Rot, UK) and subjected to selection with zeocine (200 µg/ml)
(Invitrogen) for 14–21 days. Thirty single clones were isolated by using cell cloning
cylinders transferred and grown stepwise for expansion to 107 cells. As a control, we used
cell clones transfected with the empty pTer vector or with pTer/Scr vector. For inducible
siRNA experiments, doxycycline (Sigma) was added to the cell culture medium at the final
concentration of 1 µg/ml and cells were grown for the indicated times. Total cellular extracts
were analyzed for APE1 expression by immunoblotting.
All biological data were reproduced in at least two different cell clones for each model.
2.2 Cell growth assays, cell cycle and apoptosis studies
For proliferation assays, cells were harvested at indicated times, stained with Trypan blue
(Sigma), plated in triplicate and counted. Clonogeneic assay was performed according to
Plumb [16]. Briefly, an equal number (500) of control and siRNA cells were plated in petri
dishes and grown with medium containing or not doxycycline (1 µg/ml). On day 10, the
medium was removed and colonies were stained for 2 min with 2 ml of cristal violet
solution (10% w/v in 70% aqueous ethanol). The dye was then poured off. Then, plates were
rinsed with tap water and allowed to dry. Colonies were counted by using ImageQuant TL
software (GE Healthcare, Milan, Italy). For each experimental point, the mean, SD and
statistical significance were calculated performing three independent experiments of cell
colony count.
Cell cycle studies were performed by flow cytometry by using a FACScan (Becton
Dickinson, Franklin Lakes, NJ, USA). The number of apoptotic cells in control and APE1
siRNA cells after 0 and 10 days of treatment with 1 µg/ml of doxycycline was determined
using the method of Nicoletti et al. [17] by evaluating the number of cells with subdiploid
DNA content through flow cytometric determination. Briefly, 2 × 106 cells were harvested
and washed once with cold PBS/0.1% w/v sodium azide solution, resuspended in 1 ml of
low-salt stain solution [4 mM sodium citrate, 3% v/v polyethylene glycol 8000, 1 mg/ml
propidium iodide solution (Invitrogen, Carlsbad, CA, USA), 180 U/ml RNAse A (Sigma)
and 1% w/v Triton X-100 in PBS/sodium azide solution] and then incubated, in the dark, at
37 °C, for 20 min, with gentle mixing every 5 min. Then, 1 ml of high-salt stain solution
(0.4 M sodium chloride, 3% v/v polyethylene glycol 8000, 1 mg/ml propidium iodide
solution and 1% w/v Triton X-100 in PBS/sodium azide solution) was added by gentle
pipetting and samples were stored at 4 °C overnight. Cells were centrifuged at 5000 × g for
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5 min, at 4 °C, the supernatant was removed, pellet resuspended in 500 µl of low-salt
solution and then cells were analyzed on a Becton-Dickinson Canto using an Ar laser
(excitation 488 nm). For each sample, 25,000 single events were detected and data analysis
was performed using both WinMDI 2.8 (written by Joseph Trotter, Scripps Research
Institute, La Jolla, CA) and ModFitLT V3.0 software program.
2.5 Preparation of cell extracts and Western blot analysis
To obtain total protein extracts, 107 HeLa cells were directly lysed into lysis buffer
containing 7.0 M urea, 2.0 M thiourea, 2% w/v 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonic acid, 10 mM DTT, 1% v/v carrier
ampholytes pH 3–10 (GE Healthcare), 1% (v/v) β-mercaptoethanol and 40 mM Tris-HCl, by
using a potter. Samples were lysed in a total volume of 500 µl. Homogenates were then
centrifuged at 10,000 × g for 30 min, at 4 °C, and supernatants collected for the following
analysis or stored at −80 °C. Protein quantification was performed by the Bradford
colorimetric method [18] and SDS-PAGE analysis.
Cell nuclear and cytoplasmic extracts were prepared as previously described [19]. Briefly,
107 cells were washed once with PBS and resuspended in 100 µl of hypotonic lysis buffer A
(10 mM Hepes, 10 mM KCl, 0.1 mM MgCl2, 0.1 mM EDTA, 2 µg/ml leupeptin, 2 µg/ml
pepstatin, 0.5 mM PMSF, pH 7.9). After 10 min, cells were homogenized by ten strokes
with a loose-fitting Dounce homogenizer. Nuclei were collected by centrifugation at 500 ×
g, at 4 °C, for 5 min, in a microcentrifuge. The supernatant was considered as the
cytoplasmic fraction. Nuclei were then washed three times with the same volumes of buffer
A to minimize cytoplasmic contamination. Nuclear proteins were extracted with 100 µl of
buffer B (10 mM Hepes, 400 mM NaCl, 1.5 mM MgCl2, 0.1 mM EDTA, 2 µg/ml leupeptin,
2 µg/ml pepstatin, 0.5 mM PMSF, pH 7.9). After incubating for 30 min at 4 °C, samples
were centrifuged at 12,000 × g for 20 min, at 4 °C. Nuclear extracts were then analyzed for
protein content [18] and stored at −80 °C in aliquots.
Western blot analysis were performed on the indicated amounts of cell extracts as described
previously [19]. Normalization was performed with the polyclonal anti-actin or anti-β-
tubulin antibodies (Sigma). Blots were quantified by using a Gel Doc 2000
videodensitometer (Bio-Rad, Hercules, CA, USA).
2.6 Two-dimensional polyacrylamide gel electrophoresis
Thirty µg of total cell extracts were loaded onto 13 cm, pH 3–10 L IPG strips (GE
Healthcare). IEF was conducted using an IPGPhor II system (GE Healthcare) according to
the manufacturer’s instructions. Focused strips were equilibrated with 6 M urea, 26 mM
DTT, 4% w/v SDS, 30% v/v glycerol in 0.1 M Tris-HCl (pH 6.8) for 15 min, followed by 6
M urea, 0.38 M iodoacetamide, 4% w/v SDS, 30% v/v glycerol, and a dash of bromophenol
blue in 0.1 M Tris-HCl, pH 6.8, for 10 min. The equilibrated strips were applied directly to
10% w/v SDS-polyacrylamide gels and separated at 130 V. Gels were fixed and stained by
ammoniacal silver [20]. Gels were scanned with an Image Master 2-D apparatus and
analyzed by the Melanie 5 software (GE Healthcare), which allowed estimation of relative
differences in spot intensities for each represented protein.
2.7 Evaluation of differentially-represented spots and mass spectrometry analysis
Each sample was analyzed in triplicate; then, a comparative analysis was carried out as
previously reported [21] (see Supplementary Material for details). Differential spots from 2-
DE were excised from the gel, triturated and washed with water. Proteins were in-gel
reduced, S-alkylated and digested with trypsin as previously reported [21]. Digested aliquots
were removed and subjected to a desalting/concentration step on µZipTipC18 (Millipore
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Corp., Bedford, MA, USA) using acetonitrile as eluent before MALDI-TOF-MS analysis.
Peptide mixtures were loaded on the MALDI target, using the dried droplet technique and α-
cyano-4-hydroxycinnamic acid as matrix, and analyzed by using Voyager-DE PRO mass
spectrometer (Applied Biosystems, Framingham, MA, USA). Spectra were elaborated using
the DataExplorer 5.1 software (Applied Biosystems) and manually inspected to get the peak
lists. Internal mass calibration was performed with peptides deriving from enzyme
autoproteolysis. PROWL software package was used to identify spots unambiguously from
updated all taxa non-redundant sequence database (NCBI nr 2008/05/03) by using a mass
tolerance value of 40–60 ppm, trypsin as enzyme specificity, a missed cleavages maximum
value of 2 and cysteine carbamidomethyl and methionine oxidation as fixed and variable
modification, respectively. Candidates with ProFound’s Est’d Z scores > 2.0 were further
evaluated by the comparison with their calculated mass and pI using the experimental values
obtained from 2-DE. Detailed PMF analysis is reported in the supplemental data.
2.8 Microarray analysis
Total RNA was extracted in triplicate by using TRIzol reagent kit (Invitrogen), and
quantified. The total RNA quality was determined using the Agilent Bioanalyser (Agilent
Technologies, Stockport, Cheshire, UK). Human genome HG U133 PLUS2 microarrays
were run according to manufacturer’s instructions (Affymetrix Inc., Santa Clara, CA, USA)
and submitted in MIAME (Minimum Information About a Microarray Experiment)-
compliant format to the ArrayExpress database (www.mged.org/Workgroups/MIAME/
miame.html, accession number E-MEXP-1315). Array data were normalized and
summarized using RMAExpress [22]. Differential expression in response to siRNA
treatment was calculated using Cyber-T [23]. A false-discovery correction was applied to
these p-values to produce a q-value [24].
2.9 Reconstruction of the APE1 response network
Network construction was performed with MetaCore software (Genego Inc, St. Joseph, MI,
USA). This software builds networks based on human annotated relationships between
proteins based on peer reviewed publications.
2.10 Statistical analysis
Statistical analysis was performed using the Microsoft Excel data analysis program for
Student’s t-test analysis. P<0.05 was considered as statistically significant.
3. Results
3.1 Biological effects of endogenous APE1 downregulation by conditional siRNA
Conditional knock-down by RNAi technology was chosen to study molecular changes, at
the protein and gene expression levels, associated to loss of APE1 functions. We used HeLa
cells as a general cellular model for this study. Endogenous expression of APE1 was
knocked-down by siRNA technology in a conditional manner through a doxycycline-
responsive promoter [15]. Control HeLa cells, obtained after stable transfection with the
control siRNA empty vector (pTer) or with a scrambled sequence (pTer/Scr), or silenced
HeLa cells bearing the APE1 specific siRNA plasmid (pTer/APE1), were treated with
doxycycline for different times up to fifteen days and the expression levels of APE1 were
evaluated each day (Figure 1A). Neither stable transfection with the empty vector nor with
the scrambled sequence affected the endogenous expression level of APE1 protein. On the
contrary, inducible expression of APE1 siRNA sequences efficiently promoted APE1 down-
regulation in a time-dependent manner. At ten days of treatment, endogenous APE1
Vascotto et al. Page 5
Proteomics. Author manuscript; available in PMC 2013 October 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
expression was almost undetectable as compared to both controls. This time point was
therefore chosen for further gene expression and proteomics analysis.
Progressive reduction of endogenous APE1 levels was paralleled by: i) a concomitant loss of
the AP-endonuclease activity of nuclear extracts in silenced cells and ii) a parallel increase
in AP-sites accumulation on genomic DNA was observed (Supplementary Figs. 1A and B).
These data were confirmatory of the role of APE1 as the major AP-endonuclease enzyme in
eukaryotic cells.
Next, we evaluated the effects of loss of APE1 expression on cell proliferation, cell cycle
and apoptosis. While direct cell counting and clonogeneic proliferation assays clearly
showed a strong inhibition of cell growth in the silenced clone that paralleled the reduction
in the endogenous APE1 levels, control clones were not affected (Fig. 1A, 1B and 1C).
These results suggest that, similarly to previously reported evidence using different cell lines
[1], APE1 levels affect cell division. In order to test whether the observed reduction of cell
proliferation following APE1 down-regulation was the result of induction of apoptosis or of
inhibition of the cell cycle, apoptosis and cell cycle analyses were performed.
3.2 APE1 knocked-down cells undergo apoptosis and bear impaired cell cycle
Silencing of APE1 caused an increase in cell death by apoptosis. Flow cytometry analysis
performed on control and silenced clones showed a strong correlation between down-
regulation of APE1 expression and increased apoptosis (Fig. 2A). In particular, at 10 days of
treatment with doxycycline (when APE1 expression level in the silenced clone is minimal),
25% of the cell population appeared in the flow histogram as sub-G1 peak corresponding to
apoptotic cells possessing a sub-diploid DNA content (Fig. 2A, right). Apoptosis analysis
performed by Annexin-V staining confirmed these results (data not shown).
Given these findings, we concentrated on the relationship between cell-death and cell cycle
progression following APE1 silencing. Increased cell-death in APE1-deficient cells was
associated to an increase in S-G2/M versus G1 population ratio (Fig. 2B), as measured by
FACS-analysis. In fact, in the APE1-silenced clone, the percentage of cycling cells
decreases according with the observed increase in apoptosis upon induction with
doxycycline (time 0 of induction: 87.05% cycling cells; 10 days and 12 days: 64.62% and
57.99% of cycling cells, respectively). This phenomenon did not occur for the control clone
(time 0: 85.75% of induction; time 10 days: 81.85%, time 12 days 83.11%). Among the
cycling population, we observed a decrease in the ratio between G1 and S+G2-M phases
upon APE1 silencing. In the APE1-silenced clone, at time 0 of induction with doxycycline,
the G1/S+G2-M ratio was 1.43, whereas at time 10 days this ratio was 0.96 and at time 12
days it was 0.73. For the control clone, the G1/S+G2-M ratios were almost constant, being
1.46 at time 0 of induction and 1.33 and 1.46 at time 10 and 12 days, respectively. This
evidence led us to hypothesize that APE1 silencing impairs the passage from S-G2/M phases
to the following G1 phase. This hypothesis was verified by synchronization experiments
(Supplementary Fig. 2). These data were suggestive for a pivotal role of APE1 in controlling
cell cycle progression and the importance of its functions in cell surviving, opening also
different scenarios in which APE1 plays a role not only in DNA repair but also in the redox
transcriptional co-activation of genes involved in cell-cycle progression and in the redox-
mediated cell signalling, functions still largely unexplored.
3.3 APE1 loss-of-expression impairs cell growth, signal transduction, cytoskeletal
structure, oxidative stress and DNA-repair-related genes
In order to identify the molecular changes associated to the loss of APE1 expression, we
adopted an unbiased differential proteomic approach, based on 2-DE gel quantitative
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analysis coupled to MALDI-TOF-MS identification of the up/down-regulated proteins, and
a differential gene expression approach based on microarray analysis.
To obtain more information during the proteomic investigation, the analysis was performed
on total, nuclear and cytoplasmic extracts, respectively. Silver staining of 2-DE allowed for
the visualization and simultaneous quantitative evaluation of about 600–700 protein spots in
each gel (Fig. 3). A total of 10 different proteins displayed a statistically significant change
in knocked-down cells as compared to the control cells (Table 1 and Supplementary
Material Fig. 3). Peptide mass fingerprint analysis and non-redundant sequence database
searching allowed the non-ambiguous identification of all the analyzed species. Table 1
reports the nature of each identified spot, the measured 2-DE coordinates and relative
sequence coverage, together with their relative abundance. Six of them were up-regulated
(ANXA3, BPNT1, DDX39, GRB2, ACTB, CLIC3) and four (GDIB, GUAD, COPE,
MARE1) were down-regulated in the APE1 knocked-down cell clone. It is noteworthy that
all the proteins belong to functional categories involved in signal transduction (ANXA3,
GRB2, GDIB, CLIC3), cytoskeletal structure and intracellular trafficking (DDX39, COPE,
MARE1, ACTB) and metabolism (BPNT1 and GUAD).
To identify genes whose expression changed as a consequence of APE1 silencing, we
compared the gene expression profiles of WT and APE1 knocked-down cell clones by using
the human Affimetrix GeneChip (HG-U133 PLUS2), which comprises over 20,000 genes.
Three replicated RNA preparations from independent individual cultures of WT and APE1
silenced HeLa cells were hybridized to six arrays. In general, a gene was considered to be
differentially expressed in APE1-deficient cells when the q-value was less than 0.05, the
fold change was greater than or less than 1.5 and the mean expression level intensity was
greater than 100 in either sample. By using these criteria, 1126 genes were identified as
differentially expressed. Of these, 550 were identified as up-regulated and 576 down-
regulated in APE1 deficient HeLa cells. Some of the differentially expressed genes
corresponded to eight of the differentially expressed proteins already found by proteomic
analysis (i.e. ANXA3, BPNT1, GDIB, GUAD, DDX39, GRB2, CLIC3, ACTB), suggesting
that changes found at the protein level were due to transcriptional regulation. Interestingly,
an already hypothesized target gene, i.e. that of the transcription factor Egr-1 [9], was
identified by our analysis. Other notable genes are listed in Supplementary Table 1 (see the
Supplementary Table 2 for the complete list of differentially expressed genes).
To confirm the microarray gene expression data, the expression level of 10 differentially
expressed genes was also determined by Q-PCR as well as by Western blotting analysis
(Supplementary Fig. 3). The fold induction/repression calculated by Q-PCR and Western
blot analysis was in remarkable agreement with the corresponding ratio determined in the
Affimetrix GeneChip analysis. Overall, a concordant behaviour between gene expression
and proteomic data was proved for 20 different genes (see Supplementary Table 3 and Table
4).
Functional annotation of the microarray data was performed with DAVID [25]. Genes up-
regulated by APE1 silencing showed a strong over-representation of cytoskeleton and
microtubule components. There was also over-representation of extracellular matrix
components, lipid metabolism, positive regulation of I-kappaB kinase/NF-kappaB cascade,
and cell cycle arrest genes. Genes down-regulated by APE1 silencing included genes
involved in cell growth, protein biosynthesis, DNA repair, cell cycle, mitochondria location,
and oxidoreductase activity.
We sought to integrate the disparate consequences of APE1 silencing into a series of
relationships. Networks were constructed based on published relationships between proteins
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using MetaCore software. A summary of these relationships is shown in Fig. 4. APE1
functionally interacts with molecular components of the cell responsible for dealing with
oxidative stress, mitochondria, DNA damage, microtubules and signal cascades. APE1
silencing could lead to apoptosis and/or cell growth arrest through any one or several of
these cellular perturbations.
We performed a series of experiments to evaluate the validity of these molecular findings at
the biological level (Fig. 5 and Supplementary Material Figs. 5 and 6). To define the role of
mitochondria in cell death due to APE1-loss-of-expression, the mitochondrial membrane
potential (Δψm), and the release of mitochondrial apoptosis effector Cytochrome-c (Cyt-c)
and Apoptosis Inducing Factor (AIF) were studied. We clearly observed that APE1 silencing
caused impairment of mitochondrial function, as measured by Δψm membrane potential
depolarization, which was associated with Cyt-c and AIF release. These results may account
for apoptotic triggering through the intrinsic pathway (Fig. 5A and Supplementary Material
Fig.5).
Based on the alteration in redox signalling, as derived from genome-wide and proteomics
data, we measured both the intracellular ROS and the protein carbonyl content upon APE1
loss of expression. We found that APE1 silencing is associated to a pro-oxidant cellular
status, as measured by increased ROS production, as a consequence of NADPH oxidase
hyperactivation and increase in the protein carbonyl content (Fig. 5B and Supplementary
Material Fig.6).
Finally, we asked whether cytoskeletal organization was disturbed in APE1 silenced cells.
Confocal microscopic observations revealed a substantial disorganization of the actin stress
fibers associated with membrane ruffling in APE1 knocked-down cells. In all the clones,
with the exception of APE1 siRNA clone treated with doxycycline, the cells appeared
flattened and well spread, with actin arranged in parallel arrays of long and almost
continuous stress fibers running through the cytosol (Fig. 5C). Notably, upon APE1
silencing, a drastic reorganization of the F-actin network was observed in a way that the
cytosolic stress fibers almost completely disappeared and actin aggregates were accumulated
in a cortical mantle.
4. Discussion
Despite the central role played by APE1 in mammalian cell viability, comprehension of the
molecular signalling networks underlying the multifaceted action of APE1 is yet elusive.
Achieving such an understanding may be of great relevance in explaining why attempts to
revert the apoptosis due to APE1 suppression via sole targeting of the DNA-repair
enzymatic activity of APE1 in knocked-down or knocked-out mammalian cells were
unsuccessful. With this goal in mind, the aim of this study was to use an unbiased strategy,
by combining both mRNA expression profiling and proteomic analysis, to investigate the
molecular changes associated to APE1 loss-of-expression by siRNA technology. A series of
molecular evidences came out from this study, some of them providing a more solid base to
already published data, which led us to build up the molecular networks reported in Fig. 6.
However, the main message of this work is that APE1 represents a hub in coordinating
different functions in mammalian cells. Thus, particular care must be taken in the future
studies to understand the fine-tuning mechanisms responsible for its functional regulation.
APE1 is strongly associated with the Thioredoxin system and with the COP9 signalosome
complex
One interesting aspect of the network derived from this work is the Thioredoxin (TRX)
system. APE1 directly binds to TRX in the nucleus [26]. The TRX/APE1 complex then
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regulates the activity of DNA-binding proteins by redox modification(s) of specific cysteine
residue(s); these include Jun/Fos (AP-1), nuclear factor-kappaB (NF-κB) and p53 [27–30].
We realized that several of these transcription factors display altered expression (and
possible impaired functional activity) in our APE1 silenced cells. This finding perfectly
matches with the alteration of expression of a number of their target genes (Fig. 6A). After
abolishment of APE1 expression by siRNA, a significant perturbation of the redox cellular
environment occurs, consistent with our findings of increased cellular oxidative stress
condition. Expression of TRX, however, did not change significantly. Nonetheless, we
found a relevant down-regulation of TXNIP (VDUP1), which directly binds to reduced
TRX, forming a stable disulfide-linked complex [31]. The involvement of APE1 in the TRX
system can explain, at least in part, the extensive biological consequences on cell growth
that we observed after APE1 down-regulation and may also explain APE1 implication in
different pathogenetic events (see below) such as cancer [32].
Our gene expression data showed a significant down-regulation of the Jun activation
domain-binding protein 1 (JAB1), another protein known to directly bind to TRX and
TXNIP [33]. JAB1 binds the nuclear progesterone receptor (PR) and binds to and thus
coactivates transcription activation factors AP-1 and Src-1 [34]. Interestingly, both AP-1 and
Src-1 have been already suggested as APE1-regulated proteins [6, 35]. Nuclear receptors,
their coactivators and coregulators are present in large multimeric complexes [36], whereas
JAB1 is localized in the COP9 signalosome complex. COPS5, one of the 8 proteins in the
COP9 signalosome complex, also showed a significant down-regulation in our experiments
after silencing of APE1 expression (Fig. 6A). Therefore, we can speculate that APE1 takes
part to important general processes of intracellular signalling transduction pathways.
The induction of stress proteins gene expression, such as Hsp70 (Fig. 6A), may be
ascribable to adaptive cellular response mechanisms to the stress condition due to APE1
loss-of-expression. Similarly, up-regulation of NF-κB signalling cascade could be
interpreted as a pro-survival program, triggered to escape apoptosis due to APE1 loss-of-
expression.
APE1 silencing leads to mitochondrial-mediated apoptosis
APE1 silencing induces apoptosis. Our data provide no definitive evidence in favor of a
single model of induction of apoptosis (Fig. 4), even though a major involvement of
mitochondrial-mediated apoptosis is plausible. Mitochondrial localization of APE1 may be
associated to a potential role in DNA repair of oxidized bases in mitochondrial genome [2,
37, 38]. Accumulation of mtDNA oxidative damage may negatively impact the expression
of proteins involved in respiratory chain activity, which leads to impairment in oxidative
phosphorylation, and in mitochondrial malfunctioning, causing, in turn, enhanced ROS
production. These events would perpetuate the damage and constitute a ‘vicious cycle’
exacerbating the original oxidative offence. In accordance with these hypotheses, we were
able to demonstrate a significant impairment in mitochondrial functionality upon APE1
silencing, as determined by mitochondrial membrane potential depolarization assays. At
present, our data are suggestive of a major involvement of mitochondrial pathways in the
apoptotic process associated to APE1 loss-of-expression, as demonstrated by release of Cyt-
c and AIF perinuclear accumulation in APE1 silenced cells. Further experiments are needed
to address this issue. Of interest, is the observation that mitochondrial antioxidant proteins
(i.e. PRDX3, NOXA) were also found down-regulated upon APE1 gene silencing,
suggesting that the role of APE1 within mitochondria could be also indirect.
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APE1 controls the intracellular redox state
Mitochondria are the major source of ROS within eukaryotic cells. However, other
multienzymatic protein complexes may affect intracellular ROS production. This is the case
of the non-phagocytic NADPH oxidase system, which is an enzyme composed of multiple
membrane-associated (Mox and p22phox) and cytosolic components (p67 phox, p47phox,
Rac1), which catalyzes the transformation of the molecular oxygen to the superoxide anion
by transferring an electron from the substrates NADH or NADPH [39]. It has been recently
suggested that APE1 may inhibit Rac1 activity in vivo, thus possibly controlling
intracellular ROS production [40, 41]. However, those findings were obtained by over-
expressing ectopic APE1 in cell models, and therefore did not definitely demonstrate a
causal role for APE1 in the process due to the presence of non-physiological amount of
APE1. Here, by using the specific NADPH oxidase inhibitor apocynin, we ultimately
showed that indeed APE1 plays an inhibitory role on ROS production by the membrane
NADPH system. Since we recently demonstrated that NADPH-mediated ROS production
induced by P2Y triggering was able to promote APE1 functional activation [19], we propose
the existence of an autoregulatory loop between these two systems. This observation will be
of therapeutical relevance for endothelial, fibroblastic and smooth muscle cells in vascular
system pathologies, where an over-activation of the NADPH oxidase system is involved
[42], as well as in the angiogenesis process [43], where a further hypothesis of
autoregulatory loop between APE1 and VEGF may be inferred [44]. This observation could
be therapeutically relevant also for treatment of tumor progression and cancer metastasis.
APE1 controls the cytoskeletal structure
During mitosis, complete disassembly and reassembly of all the cytoskeletal components is
required. The pathways that link cell activation to cytoskeletal changes are the key to the
transmission of signals for the pleiotropic effects necessary for appropriate cellular response.
A number of genes associated with cytoskeletal structures were identified through our
microarrays analysis. This is suggestive of a major role of cytoskeleton downstream of
APE1. Actin, an element of the microfilaments, exerts important functions in cell motility,
mitosis and intracellular trafficking and changes in the dynamics/distribution of this
cytoskeletal protein are observed during apoptosis. Though the involvement of cytoskeletal
actin in apoptosis is still poorly understood, its causal role seems to be clear [45]. In this
study, a major disorganization of actin stress fibers associated with membrane ruffling
paralleled the loss of APE1 expression. Thus, it seems likely that many of the morphologic
manifestations of apoptosis, as well as the general effects on signal transduction pathways,
are linked to the disassembly of the rigid cytoskeleton. A further perspective of this
observation would be a possible role of APE1 in controlling cell migration via cytoskeleton.
Egr-l is a direct functional target of APE1
The unbiased approach we used in identifying new genes directly or indirectly regulated by
APE1 was a useful tool to confirm the multifaceted nature of APE1. Based on gene
expression data, we found that the expression levels of Egr-1 strictly depend on the presence
of APE1. The fact that APE1 is also able to regulate Egr-1 expression levels, in addition to
act as a redox coactivator over Egr-1 transcriptional activity [8, 9], reinforces our previous
hypothesis of a functional regulatory loop between APE1 and Egr-1 [9]. This finding also
underlines the biological complexity typical of this multi-functional protein and could
constitute a means through which APE1 may regulate the expression of DNA repair genes
such as GADD45 [46]. Egr-1 activates the transcription of cell-growth associated genes in
response to a variety of mitogenic and non-mitogenic stimuli, including growth factors and
hypoxia [47, 48] and is able to form redox-modulated transcriptional complexes with the
above mentioned transcription factors (i.e. AP-1), as well as with APE1 and TRX [49].
Thus, in light of the new evidence presented by our results, the role of Egr-1 seems pivotal.
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The central effect of APE1 on Egr-1 biological functions is also reinforced by the
concomitant down-regulation of additional Egr-1 target genes, such as C/EBPβ, VEGF and
c-Myc (see Fig. 5B) [50].
Future perspectives for understanding APE1 roles in human pathologies
Overall, our data convincingly show a leading role for APE1 in controlling the cellular
redox state both through the intracellular ROS production level in the cytoplasm and through
the nuclear redox state by means of the TRX system, resulting in the fine tuning of specific
gene expression. Modulation of the cellular redox state may affect different biological
processes involved in cell growth, inhibition of apoptosis and modulation of inflammation.
Therefore, the role of APE1 in a wide range of human diseases and conditions, including
cancer, ischemia-reperfusion injury, cardiac conditions, neurodegenerative diseases, aging
[2] is not surprising. However, whether APE1 contributes to or prevents the pathological
progression of a particular condition is not always clear. For example, in several cancers, the
expression levels of APE1 are increased and the protein is often found in the cytoplasmic
compartment [2]. However, the reasons for this change in expression patterns are still poorly
understood. It can be hypothesized that under these conditions, APE1 mainly exerts
antiapoptotic and growth-promoting effects, thus playing a leading role in cancer
progression. In ischemia-reperfusion injury and in neurodegenerative disorders, in which
apoptosis contributes to the pathology, APE1 might protect against injurious insults by
promoting cell-survival programs [41, 51–53]. This dichotomous role of APE1 needs to be
explained at the molecular level by investigating the role of post-translational modifications
in controlling the different functions of the protein as well as the different interactomes in
which APE1 is enrolled. The cellular model that we characterized in this work, will be
helpful in elucidating these lines.
In summary, our data represent the first attempt to gain a global view of the molecular role
of APE1 in the cell. Combining large-scale studies with classical biochemical approaches,
we clearly showed that the wild-type APE1 protein plays a central role in different
biological processes and provides a molecular basis for explaining its multifunctional
biological activity. The dataset coming from this work also offers several scientific leads for
future studies aiming to shed light on the subtle mechanisms of this control.
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Figure 1. Effects of APE1 downregulation on cell proliferation
Panel A. HeLa cells were stably transfected with the inducible siRNA vectors, as described
in the methodological section. Suppression of endogenous APE1 expression was assayed
after different days of treatment with doxycycline (Doxy), by Western blot analysis on total
cellular extracts. Fifteen µg of total protein extracts were separated by 10% SDS-PAGE, and
then transferred onto a nitrocellulose membrane. The membrane was immunoblotted with
anti-APE1 or anti-β-tubulin antibodies (upper panel). The lower panel shows normalized
expression levels of APE1 protein obtained after densitometric analysis of the bands. Values
were reported as histograms of the ratio between APE1 and β-tubulin bands intensities.
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Black boxes represent APE1 normalized expression in the control cell clone (control) and
dashed boxes represent APE1 expression in the silenced clone (APE1 siRNA).
Panel B. Effect of APE1 silencing on cell proliferation. HeLa cells were seeded in 60 mm
petri dishes. Growth was followed by measuring cell number at various times after
doxycycline treatment. Data, expressed as the percent change with respect to control
cultures, are the mean ± SD of three independent experiments. See Materials and Methods
section for details.
Panel C. Effect of APE1 silencing on cell growth by clonogeneic assay. Five-hundred cells
of control and siRNA clones were seeded in petri dishes and then treated or not, as
indicated, with 1 µg/ml of doxycycline for 10 days. Data, expressed as percentage of
survival with respect to control cultures, are the mean ± SD of three independent
experiments and show the inhibition of colony formation due to APE1 loss of expression in
siRNA clone. (*, p < 0.05)
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Figure 2. Impaired proliferation in APE1 silenced cells is due to altered cell cycling and induced
apoptosis
Panel A. Left, evaluation of apoptosis, on isolated nuclei, on control and on APE1 siRNA
cells at 10 days of treatment with doxycycline by flow cytometry. Apoptosis is expressed as
the percentage of sub-G1 DNA containing cells (indicated by arrow), as detected by
propidium iodide (PI) DNA staining. Right, each bar of the histogram represents the mean
of three separate experiments ± SD.
Panel B. Analysis of cell cycle distribution. Control and APE1 siRNA HeLa cells were
grown in the presence of doxycycline for the indicated times. Cell cycle distribution was
evaluated at the indicated time points by FACS analysis, as described in Materials and
Methods. APE1 siRNA cells show a time-of-induction dependent decrease in the cycling
cells population, and a parallel increase in the S-G2/M versus G1 ratio.
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Figure 3. Reference 2-DE maps and differential proteomic analysis
Both control and APE1 siRNA HeLa cells were stimulated with doxycycline for 10 days and
then collected for proteomic analysis of total, nuclear and cytoplasmic extracts. All spots
showing significant changes between the two cell lines are highlighted. The identification
numbers of the spots correspond to numbering in Table 1. These spots were identified by
MALDI-TOF-MS. Protein spots numbered 1 and 8 correspond to the same protein species.
Panel B. Representative gel regions comprising some of the statistically significant changes
in proteome repertoire were cropped
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Figure 4. Inference of APE1 molecular network
Summarized networks built with MetaCore software (Genego Inc). Based on microarray
data, genes which were significantly up-regulated or down-regulated upon APE1 silencing
are shown with a red or a blue halo, respectively.
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Figure 5. APE1 silenced cells show mitochondrial depolarization, increased oxidative stress and
disturbation of cytoskeleton organization
Panel A. Control and siRNA cells (after 10 days of doxycycline treatement) were treated
with the mitochondrion specific probe JC-1. Mitochondrial depolarization was monitored by
FACS and it was measured as a red to green shift in the fluorescent emission of the dye.
FACS plots of control and siRNA cells at several times of silencing induction with
doxycycline. To define the depolarization region of the plot, cells treated with carbonyl
cyanide 3-chlorophenyl hydrazone (CCCP) were used as depolarization control. The
percentage of cell population falling in this region is marked.
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Panel B. To monitor endogenous ROS concentration, APE1 silenced-cells and control cells
were treated with the profluorophore 2’,7’-dichlorodihydrofluorescein diacetate
(H2DCFDA), which is converted in the fluorescent molecule 2’,7’-
dichlorodihydrofluorescein (DCF) upon oxidation by intracellular ROS. ROS dependent
staining was evaluated by FACS analysis. Control and APE1 silenced cells were treated for
1 h with 1 mM apocynin (apo), a specific blocker of NAD(P)H oxidase. The treatment
reduced the endogenous ROS concentration evaluated as DCF fluorescence only in APE1
siRNA clone. Left: FACS profiles of control cells (Control), siRNA cells (APE1siRNA) and
apocynin treated siRNA cells (APE1siRNA + apo) upon silencing induction. Right. To
monitor oxidative damage, protein carbonylation was quantified in APE1-deficient and
control cell extracts by derivatization with dinitrophenilhydrazine (DNPH), as described in
Supplementary Material and Methods. The derivatizated samples were subjected to dot blot
followed by recognition with anti-dinitrophenilhydrazone antibody. Histogram reporting the
densitometric values of dinitrophenilhydrazone specific signals, normalized for β-tubulin
content, in three independent experiments is shown on the right. The intensity of
dinitrophenilhydrazone staining was significantly higher in APE1 silenced than in control
cell line (*, p<0.05).
Panel C. Reorganization of F-actin in Hela cells. The effects on actin stress fibers
organization were observed by confocal microscopy after phalloidin staining. F-actin was
stained with Alexa 488-conjugated phalloidin and visualized through a Leica confocal
microscope. The amount of stress fibers in silenced clone treated with doxycycline was
clearly diminished compared with the control clones. The actin network reorganization was
associated with membrane ruffling (white arrow). Original magnification, 1000×.
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Figure 6. Different model networks for APE1-mediated signalling as derived by gene expression
and proteomic data
Direct interaction network for genes dysregulated upon APE1 knock-down, involved in
redox control, transcription regulators and chaperones (Panel A, https://portal.genego.com/
pub/network/n-839812191.html) or in Egr-1-signaling (Panel B, https://portal.genego.com/
pub/network/n-860173808.html). Colours of the symbols indicate inhibition (blue) and
activation (red). Here, the name APEX is used to refer to APE1.
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